Filters: keyword is Metabolism [Clear All Filters]
- 2009
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography,
Epilepsia, vol. 50, no. 1, pp. 88-98.
Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex,
Anesthesiology, vol. 110, no. 1, pp. 95-105.
- 2008
The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments,
J Pharmacol Toxicol Methods, vol. 57, no. 2, pp. 114-30.
Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex,
Eur J Pharm Sci, vol. 33, no. 3, pp. 217-29.
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42.
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics,
Eur J Pharm Sci, vol. 34, no. 2-3, pp. 149-63.
Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain,
Br J Pharmacol, vol. 155, no. 7, pp. 1127-38.
Extensions to the visual predictive check to facilitate model performance evaluation,
J Pharmacokinet Pharmacodyn, vol. 35, no. 2, pp. 185-202.
Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat,
Pharm Res, vol. 25, no. 4, pp. 792-804.
- 2007
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks,
Antimicrob Agents Chemother, vol. 51, no. 10, pp. 3720-5.
Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats,
J Pharmacol Toxicol Methods, vol. 56, no. 1, pp. 72-8.
Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG,
Br J Pharmacol, vol. 151, no. 5, pp. 713-20.
Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux,
Br J Pharmacol, vol. 151, no. 5, pp. 701-12.
Application of the convection-dispersion equation to modelling oral drug absorption,
Bull Math Biol, vol. 69, no. 1, pp. 181-95.
- 2006
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats,
J Pharmacol Exp Ther, vol. 319, no. 2, pp. 682-92.
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus,
J Pharmacokinet Pharmacodyn, vol. 33, no. 3, pp. 313-43.
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers,
Br J Pharmacol, vol. 148, no. 4, pp. 396-404.
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery,
Anesthesiology, vol. 105, no. 6, pp. 1135-46.
Markers of exacerbation severity in chronic obstructive pulmonary disease,
Respir Res, vol. 7, pp. 74.
- 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography,
Mol Imaging Biol, vol. 7, no. 6, pp. 411-21.
Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro,
J Control Release, vol. 103, no. 2, pp. 393-403.
Compartmental modeling of transdermal iontophoretic transport II: in vivo model derivation and application,
Pharm Res, vol. 22, no. 3, pp. 335-46.
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults,
Br J Clin Pharmacol, vol. 59, no. 6, pp. 705-11.
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics,
J Pharmacol Exp Ther, vol. 313, no. 3, pp. 1136-49.
Targeting liposomes with protein drugs to the blood-brain barrier in vitro,
Eur J Pharm Sci, vol. 25, no. 2-3, pp. 299-305.



